Clinical Trial Detail

NCT ID NCT01826448
Title A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Plexxikon
Indications

melanoma

Therapies

Pexidartinib + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST